Supriya Lifescience

Mumbai, India Founded: 2008 • Age: 18 yrs Listed
Active pharmaceutical ingredients and intermediates are manufactured.

About Supriya Lifescience

Supriya Lifescience is a publicly listed company based in Mumbai (India) founded in 2008 by Satish Wagh. Active pharmaceutical ingredients and intermediates are manufactured. The company has 555 employees. Its Indian entity Supriya Lifescience Limited reported revenue of β‚Ή839 Cr. Supriya Lifescience offers products and services including APIs and FDF. Its focus areas include Traditional Pharmaceuticals and Active Pharmaceutical Ingredients.

Company details

Supriya Lifescience was established in 2008 and is based in Mumbai, India. Operations are centered on the production of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates within the healthcare sector. Manufacturing processes are conducted to support pharmaceutical supply chains. The company is led by founder Satish Wagh. Focus remains on quality-controlled production for global markets, with activities aligned to regulatory standards in the industry.

  • Headquarters Mumbai, India
  • Employees 555
  • Founders Satish Wagh
  • Stage Public
  • Sectors
    Healthcare
  • Website supriyalifescience.com
  • Social LinkedIn X
  • Legal Name Supriya Lifescience Limited
Key Metrics
  • Market Cap
    ₹5,030 Cr

    SUPRIYA · NSE

  • Share Price
    ₹620.15

    -0.78% today

  • Revenue
    ₹828 Cr

    FY 2025-26 · +18.9% YoY

  • EBITDA
    ₹294 Cr

    Margin 35.6%

  • Net Profit
    ₹209 Cr

    FY 2025-26 · +11.3% YoY

  • P/E (TTM)
    27.9x

    P/B 4.0x

  • ROE
    19.1%

    ROCE 25.1%

  • Employee Count
    555

Products & Services of Supriya Lifescience

Supriya Lifescience offers a comprehensive portfolio of products and services, including APIs and FDF.

APIs
Pharmaceutical Products

Active pharmaceutical ingredients are manufactured and supplied for therapeutic uses in various diseases.

FDF
Pharmaceutical Products

Finished dosage forms are developed and commercialized to address infections and other health conditions.

Board of directors of Supriya Lifescience Limited (Supriya Lifescience)

Supriya Lifescience Limited is the primary company behind Supriya Lifescience. The board of Supriya Lifescience Limited currently have 10 directors; the longest-serving is Smita Satish Wagh, appointed in 2008. 16 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Smita Satish Wagh
DIN 00833912
Whole-time director26 Mar 200818 yrs 7 moSupriya Lifescience Limited
Satish Waman Wagh
DIN 01456982
Whole-time director26 Mar 200818 yrs 7 moSupriya Lifescience Limited
Neelam Yashpal Arora
DIN 01603068
Director25 Mar 20215 yrs 7 moSupriya Lifescience Limited
Saloni Satish Wagh
DIN 08491410
Managing Director01 Jul 20224 yrs 4 moSupriya Lifescience Limited
Shivani Satish Wagh
DIN 08491420
Managing Director01 Jul 20224 yrs 4 moSupriya Lifescience Limited
Balasaheb Gulabrao Sawant
DIN 07743507
Whole-time director26 May 20233 yrs 5 moSupriya Lifescience Limited
Ganapati Dadasaheb Yadav
DIN 02235661
Additional Director24 Jan 20251 yr 9 moSupriya Lifescience Limited
Sunil Subhash Bhagwat
DIN 10178976
Additional Director24 Jan 20251 yr 9 moSupriya Lifescience Limited
Manish Ishwarlal Panchal
DIN 08431492
Additional Director09 Feb 20269 moSupriya Lifescience Limited
Kothandaraman Hari
DIN 08901674
Additional Director09 Feb 20269 moSupriya Lifescience Limited

People of Supriya Lifescience

7 people are tracked at Supriya Lifescience (6 in leadership, 1 in team); the tracked headcount is 555.

NameRoleGroup
FounderLeadership
Rajesh Joshi
General ManagerLeadership
Rajeev Jain
Chief Executive OfficerLeadership
Sreekant Sreedharan
General ManagerLeadership
Krishna Raghunathan
Chief Financial OfficerLeadership
Shekhar Bhirud
Director Business Development And StrategyLeadership
Renuka Kapare
Marketing & BD Executive - EuropeTeam
Premium access

Complete people profiles for Supriya Lifescience

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Supriya Lifescience

Supriya Lifescience is a publicly listed company on the NSE with ticker symbol SUPRIYA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date28 Dec 2021
  • Listed onBSE: 543434 · NSE: SUPRIYA
  • Listed entitySupriya Lifescience Limited
  • Exchange sectorHealth technology
  • ISININE07RO01027
  • Share price₹875.60 (-0.75% on the day) · 2026-10-14
  • Market capitalisation₹7,106 Cr
  • Price to earnings35.5
  • EPS (diluted, trailing year)₹24.65
  • Dividend yield0.12%
  • Volume (last session)97,563

Financials of Supriya Lifescience

Exchange-reported figures of Supriya Lifescience Limited, the listed company behind Supriya Lifescience (NSE: SUPRIYA).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹828 Cr
+18.9% YoY
EBITDA
₹294 Cr
+12.9% YoY
Profit After Tax
₹209 Cr
+11.3% YoY
Net Worth
₹1,198 Cr
+20.2% YoY
Total Assets
₹1,205 Cr
+20.1% YoY
Total Debt
₹5.44 Cr
+1.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue828696570461530391312
Revenue growth+18.9%+22.1%+23.7%-13.0%+35.5%+25.5%-
EBITDA29426117612921417398.38
EBITDA margin+35.6%+37.5%+30.9%+28.0%+40.4%+44.3%+31.6%
Profit before tax27524816612320716796.19
Net profit20918811989.9415212473.35
Net profit margin+25.3%+27.0%+20.9%+19.5%+28.6%+31.6%+23.5%
EPS (β‚Ή)25.9823.3514.8011.1618.8616.8950.11
Balance sheet
Total assets1,2051,003822728646362253
Net worth1,198997815699616269149
Total debt5.445.385.4922.4727.4272.1982.21
Cash & bank78.8779.1574.9615822889.2874.71
Net working capital412355321386420190120
Cash flow
Cash from operations18616511363.6148.8075.89117
Cash from investing(176)(152)(174)(124)(59.82)(46.80)(25.14)
Cash from financing(9.88)(8.23)(22.36)(10.28)150(14.52)(29.23)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue206190277206200145184186
Revenue growth (YoY)+3.2%+30.8%+50.2%+11.2%+20.3%-9.7%--
Other income2.292.653.482.612.732.672.982.10
Total expenses16114217913512793.37117120
EBITDA45.4047.4697.6271.6272.6451.7067.5865.95
EBITDA margin+22.0%+25.0%+35.3%+34.7%+36.4%+35.6%+36.7%+35.5%
Depreciation9.468.948.506.826.646.456.084.96
Interest0.460.370.470.490.420.510.420.51
Profit before tax37.7740.8092.1366.9268.3147.4164.0662.58
Tax8.5316.7517.9017.2417.8912.6313.6815.80

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue206190277206200145184186
Revenue growth (YoY)+3.2%+30.8%+50.2%+11.2%+20.3%-9.7%--
Other income2.292.653.482.612.732.672.982.10
Total expenses16114217913512793.37117120
EBITDA45.4047.4697.6271.6272.6451.7067.5865.95
EBITDA margin+22.0%+25.0%+35.3%+34.7%+36.4%+35.6%+36.7%+35.5%
Depreciation9.468.948.506.826.646.456.084.96
Interest0.460.370.470.490.420.510.420.51
Profit before tax37.7740.8092.1366.9268.3147.4164.0662.58
Tax8.5316.7517.9017.2417.8912.6313.6815.80
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue828696570461530391312
Revenue growth+18.9%+22.1%+23.7%-13.0%+35.5%+25.5%-
Other income11.499.8210.649.497.585.0111.07
Total expenses533436394332316218213
Employee cost96.6880.5267.6455.5849.0832.7618.88
EBITDA29426117612921417398.38
EBITDA margin+35.6%+37.5%+30.9%+28.0%+40.4%+44.3%+31.6%
Depreciation28.4120.4415.8111.8210.126.766.41
Interest2.771.815.153.084.204.086.85
Profit before tax27524816612320716796.19
Tax65.6660.5346.5833.6355.4443.7122.84
Net profit20918811989.9415212473.35
Net profit margin+25.3%+27.0%+20.9%+19.5%+28.6%+31.6%+23.5%
EPS (β‚Ή)25.9823.3514.8011.1618.8616.8950.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.1016.1016.1016.1016.1014.6414.64
Reserves & surplus1,182981799683600254134
Shareholders' funds (net worth)1,198997815699616269149
Secured loans0.000.000.0016.6321.3066.3878.12
Unsecured loans5.445.385.495.846.125.814.09
Total debt5.445.385.4922.4727.4272.1982.21
Total liabilities--822728646362253
Assets
Gross block799534371306223123115
Net block68945331026219010098.58
Capital work in progress35.5514814967.6343.4178.7940.21
Investments98.5263.2463.8025.300.050.050.05
Inventories16011885.2511692.3172.4849.46
Sundry debtors21913411284.6611573.5051.63
Cash & bank balances78.8779.1574.9615822889.2874.71
Loans & advances74.3911012610762.1430.2119.81
Total current assets532442398465498265196
Total current liabilities12186.8776.6478.8077.5875.9075.57
Net working capital412355321386420190120
Total assets1,2051,003822728646362253
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash79.1574.9615822889.2874.7112.40
Net cash from operating activities18616511363.6148.8075.89117
Net cash from investing activities(176)(152)(174)(124)(59.82)(46.80)(25.14)
Net cash from financing activities(9.88)(8.23)(22.36)(10.28)150(14.52)(29.23)
Net change in cash(0.29)4.20(82.63)(70.33)13914.5762.31
Closing cash78.8779.1574.9615822889.2874.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+18.9%+22.1%+23.7%-13.0%+35.5%+25.5%-
EBITDA growth+12.9%+48.2%+36.6%-39.8%+23.6%+76.0%-
PBT growth+10.6%+50.0%+34.2%-40.4%+23.9%+73.9%-22.0%
Net income growth+11.3%+57.8%+32.4%-40.8%+22.8%+68.5%-
Revenue CAGR (3Y)+21.6%+9.5%+13.4%+13.9%+24.0%+22.5%+19.3%
EBITDA CAGR (3Y)+31.7%+6.8%+0.6%+9.4%+17.8%+99.1%+78.2%
Profitability & leverage
Net income margin+25.3%+27.0%+20.9%+19.5%+28.6%+31.6%+23.5%
Return on capital employed+25.1%+27.4%+22.1%+18.4%+42.0%+55.8%+46.5%
Return on net worth+19.1%+20.7%+15.7%+13.7%+34.3%+59.2%+60.4%
Debt / equity0.000.010.020.040.110.370.71
Long-term debt / equity0.000.010.010.010.010.010.04
Interest cover1.040.753.212.632.062.457.45
Efficiency & per share
Fixed asset turnover1.371.731.911.953.403.622.98
Inventory turnover6.587.686.444.967.147.077.77
Debtors turnover5.176.366.595.176.246.895.59
EPS (β‚Ή)25.9823.3514.8011.1618.8616.8950.11
Dividend per share (β‚Ή)1.001.000.800.600.600.5410.00
Book value per share (β‚Ή)148.81123.84101.3186.9176.5036.70101.84

Web traffic of Supriya Lifescience

The website of Supriya Lifescience (supriyalifescience.com) receives about 5.1K visits a month.

  • Monthly visits
    5.1K

    ▲ 6.9% vs previous month

Similar websites

Websites whose visitors overlap most with Supriya Lifescience. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
screener.in
screener.in
100%
#1,968–
nsdl.co.in
57%
1M#56,731View details

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Supriya Lifescience (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Supriya Lifescience

SUPRIYA: Q2 SL NET PROFIT 292M RUPEES VS 504M (YOY)
Exchange Update β€’ 16 days ago
SUPRIYA: Q2 EBITDA 454M RUPEES VS 726.5M (YOY); Q2 EBITDA MARGIN 22.01% VS 36.35% (YOY)
Exchange Update β€’ 16 days ago
SUPRIYA: Q2 REVENUE 2.06B RUPEES VS 2B (YOY)
Exchange Update β€’ 16 days ago
Supriya Lifescience: Hon'ble High Court Allows Provisional Release Of 200 Kg Ketamine Hydrochloride Consignment; Subject To Deposit Of ₹72 Lakh With Customs; Adjudication And Criminal Proceedings May Continue.
Exchange Update β€’ 2 months ago
Premium access

Complete news archive for Supriya Lifescience

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Supriya Lifescience

Supriya Lifescience was founded in 2008.

Supriya Lifescience is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Supriya Lifescience has 555 employees.

The primary company behind Supriya Lifescience, Supriya Lifescience Limited, reported revenue of β‚Ή839 Cr for FY 2026, up 19% year on year.

Supriya Lifescience was established in 2008 and is based in Mumbai, India. Operations are centered on the production of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates within the healthcare sector. Manufacturing processes are conducted to support pharmaceutical supply chains. The company is led by founder Satish Wagh. Focus remains on quality-controlled production for global markets, with activities aligned to regulatory standards in the industry.

Supriya Lifescience offers APIs and FDF.

Yes, Supriya Lifescience is publicly traded on NSE under the ticker symbol SUPRIYA.

Supriya Lifescience operates through Supriya Lifescience Limited.

The legal entities of Supriya Lifescience currently have 12 directors, including Smita Satish Wagh, Neelam Yashpal Arora, Balasaheb Gulabrao Sawant and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available